Template:CMV retinitis treatment: Difference between revisions
Ostermayer (talk | contribs) (Prepared the page for translation) |
Ostermayer (talk | contribs) (Marked this version for translation) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
<languages/> | <noinclude><languages/></noinclude> | ||
<translate> | <translate> | ||
====Severe Vision Threatening==== | ====Severe Vision Threatening==== <!--T:1--> | ||
<!--T:2--> | |||
*Ganciclovir intraocular implant for 8 months AND | *Ganciclovir intraocular implant for 8 months AND | ||
**Valganciclovir 900mg PO q12hrs x 14 days FOLLOWED BY 900mg PO q24hrs x 7 days | **Valganciclovir 900mg PO q12hrs x 14 days FOLLOWED BY 900mg PO q24hrs x 7 days | ||
====Peripheral lesions==== | ====Peripheral lesions==== <!--T:3--> | ||
<!--T:4--> | |||
*Valganciclovir 900mg PO q12hrs x 21 days FOLLOWED BY 900mg PO q24hrs x 7 days | *Valganciclovir 900mg PO q12hrs x 21 days FOLLOWED BY 900mg PO q24hrs x 7 days | ||
</translate> | </translate> | ||
Latest revision as of 06:46, 26 January 2026
Severe Vision Threatening
- Ganciclovir intraocular implant for 8 months AND
- Valganciclovir 900mg PO q12hrs x 14 days FOLLOWED BY 900mg PO q24hrs x 7 days
Peripheral lesions
- Valganciclovir 900mg PO q12hrs x 21 days FOLLOWED BY 900mg PO q24hrs x 7 days